Crinetics Pharmaceuticals, Inc.
NasdaqGS:CRNX Rapporto sulle azioni
Crinetics Pharmaceuticals Crescita futura
Future criteri di controllo 2/6 Crinetics Pharmaceuticals prevede che gli utili e i ricavi cresceranno rispettivamente di 17% e 62.9% all'anno. Si prevede che l'EPS crescerà di 19.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -53.9% in 3 anni.
Informazioni chiave
17.0%
Tasso di crescita degli utili
19.6%
Tasso di crescita dell'EPS
Biotechs crescita degli utili 26.7% Tasso di crescita dei ricavi 62.9% Rendimento futuro del capitale proprio -53.9% Copertura analitica Good
Ultimo aggiornamento 14 Oct 2024
Aggiornamenti recenti sulla crescita futura
Price target increased by 7.8% to US$66.43 Jun 04
Price target increased by 8.2% to US$61.50 May 12
Price target increased by 10% to US$59.79 May 07
Price target increased by 7.8% to US$57.23 Mar 20
Price target increased by 9.1% to US$54.46 Mar 13
Consensus revenue estimates decrease by 88%, EPS upgraded Mar 10
Mostra tutti gli aggiornamenti
Crinetics Pharmaceuticals, Inc. to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at the North American Neuroendocrine Tumor Society Annual Meeting Nov 13
Crinetics Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Oct 16 Crinetics Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $400 million. Oct 09
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely Oct 02
Chief Financial Officer notifies of intention to sell stock Sep 29
Crinetics Pharmaceuticals, Inc. Submits New Drug Application for Paltusotine for the Treatment of Acromegaly Sep 27
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech Aug 12 Crinetics Pharmaceuticals, Inc. Announces Marc Wilson Will Be Transitioning from His Role as Chief Financial Officer Aug 09
Chief Financial Officer notifies of intention to sell stock Jul 28
Crinetics Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 19
Chief Operating Officer notifies of intention to sell stock Jul 17 Crinetics Pharmaceuticals, Inc.(NasdaqGS:CRNX) dropped from Russell 2500 Value Index
Chief Commercial Officer notifies of intention to sell stock Jun 23 Crinetics Pharmaceuticals, Inc. Presents New Data At ENDO 2024 That Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Price target increased by 7.8% to US$66.43 Jun 04
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation Jun 01
Crinetics Pharmaceuticals, Inc. Appoints Robert M. Cuddihy as Senior Vice President of Medical Affairs May 31
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 25
Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data May 23
Price target increased by 8.2% to US$61.50 May 12
Full year 2023 earnings released: US$3.69 loss per share (vs US$3.15 loss in FY 2022) May 10
Founder notifies of intention to sell stock May 10
Price target increased by 10% to US$59.79 May 07
Crinetics Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Crinetics Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024 Apr 28
Chief Development Officer notifies of intention to sell stock Apr 17
Chief Financial Officer notifies of intention to sell stock Mar 21
Price target increased by 7.8% to US$57.23 Mar 20
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly Mar 19
Price target increased by 9.1% to US$54.46 Mar 13
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome Mar 13
Consensus revenue estimates decrease by 88%, EPS upgraded Mar 10
Consensus revenue estimates decrease by 89%, EPS upgraded Mar 06
Chief Medical Officer notifies of intention to sell stock Mar 01
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 29
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade) Feb 29 Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 29
Crinetics Pharmaceuticals, Inc. announced that it expects to receive $350.000028 million in funding from a group of investors Feb 28
Crinetics Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Chief Medical Officer notifies of intention to sell stock Feb 14
Chief Financial Officer notifies of intention to sell stock Jan 04
Crinetics Pharmaceuticals, Inc. Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome Dec 19
Chief Medical Officer notifies of intention to sell stock Dec 17
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans Nov 28
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 09
Chief Financial Officer notifies of intention to sell stock Nov 03
Chief Medical Officer notifies of intention to sell stock Oct 24
Chief Medical Officer notifies of intention to sell stock Oct 20
New minor risk - Shareholder dilution Sep 13
Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly Sep 12
Price target increased by 8.2% to US$46.78 Sep 12
Consensus revenue estimates fall by 18% Aug 15
Price target decreased by 7.4% to US$43.63 Aug 13
New minor risk - Shareholder dilution Aug 09
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth? Aug 08
Founder recently sold US$1.0m worth of stock Jul 16
Founder notifies of intention to sell stock Jul 14
Founder recently sold US$1.0m worth of stock Jun 25
Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023 Jun 22
Founder notifies of intention to sell stock Jun 19
Consensus revenue estimates increase by 154% May 12
Chief Development Officer notifies of intention to sell stock Apr 10
Chief Development Officer recently sold US$133k worth of stock Apr 06
Consensus EPS estimates fall by 13% Mar 09
Consensus EPS estimates fall by 12% Mar 07
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans Dec 31
Founder & Chief Scientific Officer notifies of intention to sell stock Dec 10
Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program Nov 29
Consensus revenue estimates fall by 37% Nov 21
High number of new directors Nov 16
Founder & Chief Scientific Officer notifies of intention to sell stock Oct 22
Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study Oct 14
Founder & Chief Scientific Officer notifies of intention to sell stock Oct 08
Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism Oct 07
Crinetics Pharmaceuticals Appoints Dana Pizzuti as Chief Development Officer Oct 04
Founder & Chief Scientific Officer notifies of intention to sell stock Sep 24
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation Sep 14
Founder & Chief Scientific Officer notifies of intention to sell stock Sep 10
Consensus forecasts updated Sep 07
Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly Sep 07
Consensus revenue estimates fall by 28% Aug 19
Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M Aug 12
Independent Director exercised options and sold US$111k worth of stock Jul 16
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate Jun 15
Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point Jun 13
High number of new and inexperienced directors Jun 01
Consensus revenue estimates fall by 13% May 26
Crinetics Pharmaceuticals, Inc. Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts May 26
Consensus revenue estimates increase by 46% May 19
Previsioni di crescita degli utili e dei ricavi NasdaqGS:CRNX - Stime future degli analisti e dati finanziari passati (USD Millions ) Data Ricavi Guadagni Flusso di cassa libero Liquidità dell'operazione Avg. Numero di analisti 12/31/2026 51 -331 -301 N/A 9 12/31/2025 12 -319 -266 -237 12 12/31/2024 2 -283 -253 -220 12 6/30/2024 1 -259 -185 -178 N/A 3/31/2024 2 -235 -184 -178 N/A 12/31/2023 4 -215 -171 -166 N/A 9/30/2023 5 -199 -167 -163 N/A 6/30/2023 5 -184 -161 -160 N/A 3/31/2023 4 -175 -144 -142 N/A 12/31/2022 5 -164 -117 -115 N/A 9/30/2022 5 -150 -104 -103 N/A 6/30/2022 5 -136 -91 -90 N/A 3/31/2022 4 -119 -82 -82 N/A 12/31/2021 1 -108 -89 -89 N/A 9/30/2021 N/A -98 -82 -82 N/A 6/30/2021 N/A -89 -74 -74 N/A 3/31/2021 N/A -79 -70 -70 N/A 12/31/2020 0 -74 -62 -62 N/A 9/30/2020 0 -67 -60 -60 N/A 6/30/2020 1 -63 -55 -55 N/A 3/31/2020 1 -59 -52 -52 N/A 12/31/2019 1 -50 -47 -46 N/A 9/30/2019 2 -44 -40 -39 N/A 6/30/2019 2 -38 -32 -31 N/A 3/31/2019 2 -31 -24 -23 N/A 12/31/2018 2 -27 -21 -19 N/A 9/30/2018 2 -21 -17 -16 N/A 6/30/2018 2 -16 -13 -13 N/A 3/31/2018 2 -12 N/A -11 N/A 12/31/2017 2 -9 N/A -9 N/A 12/31/2016 1 -6 N/A -5 N/A
Mostra di più
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che CRNX rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che CRNX rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che CRNX rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di CRNX ( 62.9% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di CRNX ( 62.9% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che CRNX non sarà più redditizia tra 3 anni.
Scoprire le aziende in crescita Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
